Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025
-
Australia falls silent, lights candles for Bondi Beach shooting victims
-
DR Congo's amputees bear scars of years of conflict
-
Venison butts beef off menus at UK venues
-
Cummins, Lyon doubts for Melbourne after 'hugely satsfying' Ashes
-
'It sucks': Stokes vows England will bounce back after losing Ashes
-
Australia probes security services after Bondi Beach attack
-
West Indies need 462 to win after Conway's historic century
-
Thai border clashes displace over half a million in Cambodia
-
Australia beat England by 82 runs to win third Test and retain Ashes
-
China's rare earths El Dorado gives strategic edge
-
Japan footballer 'King Kazu' to play on at the age of 58
-
New Zealand's Conway joins elite club with century, double ton in same Test
-
Australian PM orders police, intelligence review after Bondi attack
-
Durant shines as Rockets avenge Nuggets loss
-
Pressure on Morocco to deliver as Africa Cup of Nations kicks off
-
Australia remove Smith as England still need 126 to keep Ashes alive
-
Myanmar mystics divine future after ill-augured election
-
From the Andes to Darfur: Colombians lured to Sudan's killing fields
-
Eagles win division as Commanders clash descends into brawl
-
US again seizes oil tanker off coast of Venezuela
-
New Zealand 35-0, lead by 190, after racing through West Indies tail
-
West Indies 420 all out to trail New Zealand by 155
-
Arteta tells leaders Arsenal to 'learn' while winning
-
Honour to match idol Ronaldo's Real Madrid calendar year goal record: Mbappe
-
Dupont helps Toulouse bounce back in Top 14 after turbulent week
-
Mbappe matches Ronaldo record as Real Madrid beat Sevilla
-
Gyokeres ends drought to gift Arsenal top spot for Christmas
-
Arsenal stay top despite Man City win, Liverpool beat nine-man Spurs
-
US intercepts oil tanker off coast of Venezuela
-
PSG cruise past fifth-tier Fontenay in French Cup
-
Isak injury leaves Slot counting cost of Liverpool win at Spurs
-
Juve beat Roma to close in on Serie A leaders Inter
-
US intercepts oil tanker off coast of Venezuela: US media
-
Haaland sends Man City top, Liverpool beat nine-man Spurs
-
Epstein victims, lawmakers criticize partial release and redactions
-
Leverkusen beat Leipzig to move third in Bundesliga
-
Lakers guard Smart fined $35,000 for swearing at refs
-
Liverpool sink nine-man Spurs but Isak limps off after rare goal
-
Guardiola urges Man City to 'improve' after dispatching West Ham
-
Syria monitor says US strikes killed at least five IS members
-
Australia stops in silence for Bondi Beach shooting victims
-
Olympic champion Joseph helps Perpignan to first Top 14 win despite red card
-
Zelensky says US mooted direct Ukraine-Russia talks on ending war
-
Wheelchair user flies into space, a first
-
Brazil's Lula, Argentina's Milei clash over Venezuela at Mercosur summit
-
Haaland sends Man City top, Chelsea fightback frustrates Newcastle
-
Thailand on top at SEA Games clouded by border conflict
-
Chelsea chaos not a distraction for Maresca
-
Brazil's Lula asks EU to show 'courage' and sign Mercosur trade deal
-
Africa Cup of Nations to be held every four years after 2028 edition
NYSE - LSE
Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025
DENVER, CO / ACCESS Newswire / September 16, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its fiscal 2025 full year and fourth quarter, after the market close on Tuesday, September 23, 2025. The Company has scheduled a conference call and webcast that same day, Tuesday, September 23, 2025, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
Conference Call Details
Date and Time: Tuesday, September 23, 2025, at 4:30 p.m. Eastern time.
Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 447137.
Webcast Information: The webcast will be accessible live and archived at https://www.webcaster5.com/Webcast/Page/2142/52803, and accessible on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations.
Replay: A teleconference replay of the call will be available until October 7, 2025, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 52803.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), and a line of legacy products, including Karbinal® ER (carbinoxamine maleate), Poly-Vi-Flor® and Tri-Vi-Flor®. To learn more, please visit aytubio.com.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
[email protected]
Robert Blum
Lytham Partners
[email protected]
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
A.Jones--AMWN
